Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Opts In To ROR Gamma T Inhibitor Space With Orca Collaboration

This article was originally published in The Pink Sheet Daily

Executive Summary

BioMotiv spinout could realize up to $122.5 million under arrangement giving AstraZeneca global option rights to a late-stage preclinical program for producing drugs that regulate production of IL-17.

Advertisement

Related Content

Deal Watch: After Novartis Deal, GSK Increases Vaccine Emphasis With GlycoVaxyn Buyout
Autoimmune RORγt Program May Portend Change Of Direction For Vitae

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS078206

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel